Skip to main content
Clinical Trials/NCT01828931
NCT01828931
Completed
Not Applicable

Effectiveness of Intensive Lifestyle Interventions in the Management of Diabetes in Individuals With Psychosis

Centre for Addiction and Mental Health1 site in 1 country120 target enrollmentDecember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Centre for Addiction and Mental Health
Enrollment
120
Locations
1
Primary Endpoint
HbA1c levels
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population. Life expectancy of individuals with psychosis is also 20-25 years less than the general population, primarily due to premature onset of cardiovascular disease (CVD). Despite the high risk for T2DM and CVD, psychotic illness has been an exclusion criterion in all large-scale studies of diabetes prevention and management. We propose a 3-year randomized controlled trial examining the effectiveness of a lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity in overweight or obese individuals (N=150) suffering from both a psychotic illness and T2DM. Weight and glycemic control will be the primary outcome variables. It is hypothesized that a significant weight reduction and improvement in glycemic control will be found in those who receive the LI relative to those who do not.

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
November 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Margaret Hahn

Staff Psychiatrist

Centre for Addiction and Mental Health

Eligibility Criteria

Inclusion Criteria

  • Between the ages of 18 and 70 years (inclusive)
  • DSM-IV-TR diagnosis of one of the psychotic disorders listed above
  • Body Mass Index (BMI) \> 25 kg/m2 at the time of enrollment
  • Clearly documented diagnosis of type-2 diabetes mellitus or prediabetes
  • Ability to provide informed consent
  • No medical contraindication to participation in weight reduction / exercise program, determined in consultation with their primary care physician
  • Female participants, of childbearing potential, using a medically accepted means of contraception

Exclusion Criteria

  • Inability to give informed consent
  • Currently enrolled in a formal structured weight management program
  • Currently being prescribed medication specifically for weight loss
  • Participants with unstable or active cardiovascular illnesses (myocardial infarction, CHF, etc), active or end-stage renal disease, unstable thyroid disease, etc.
  • Recurrent episodes of diabetic ketoacidosis, seizure or coma without warning or severe hypoglycemia

Outcomes

Primary Outcomes

HbA1c levels

Time Frame: 52 weeks

Weight

Time Frame: 52 weeks

Study Sites (1)

Loading locations...

Similar Trials